# An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

> **NCT00487435** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 1166 (actual)

## Conditions studied

- Pain
- Osteoarthritis
- Low Back Pain

## Interventions

- **DRUG:** Tapentadol (CG5503) Extended Release (ER)

## Key facts

- **NCT ID:** NCT00487435
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 1166 (ACTUAL)
- **Last updated:** 2014-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00487435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00487435, "An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00487435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*